Sun Pharma Advanced Research Company share news, announcements and annual reports
NSE: SPARCBSE: 532872Pharmaceuticals & BiotechnologySmall Cap
Share price at the NSE close on 28 Oct 2026. Previous close ₹179.24.
28 Oct: open ₹180.63, high ₹184.30, low ₹178.35
- Next results date: the board meets on 2 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹5,928 Cr778th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 3.74
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 4.43
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the latest balance sheet's; the one a year before is not on record.
- 118.4%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 84.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.42
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 4,34,66631.5% delivered
Sun Pharma Advanced Research Company has 577 announcements on record, routine notices left out; 2 in the 30 days to 28 Oct 2026, the latest on 22 Oct 2026.
Next board meeting and results date
As the company gave notice to the exchange.Sun Pharma Advanced Research Company quarterly results
The board meets on 2 Nov 2026 to consider financial results
Notice filed 22 Oct 2026
To consider and approve the financial results for the quarter and half year ended September 30, 2026
Sun Pharma Advanced Research Company annual reports, presentations and earnings calls
The company's own documents, latest first.Sun Pharma Advanced Research Company financials, year by year
Annual reports17
- Annual report, year to Mar 20266 Oct 2026
- Annual report, year to Mar 202518 Jul 2025
- Annual report, year to Mar 202418 Jul 2024
- Annual report, year to Mar 202314 Jul 2023, a zip file
- Annual report, year to Mar 20223 Sep 2022, a zip file
12 earlier reports
- Annual report, year to Mar 20217 Sep 2021, a zip file
- Annual report, year to Mar 20207 Sep 2020, a zip file
- Annual report, year to Mar 20195 Jul 2019, a zip file
- Annual report, year to Mar 20181 Aug 2018, a zip file
- Annual report, year to Mar 20179 Aug 2017, a zip file
- Annual report, year to Mar 201630 Jul 2016, a zip file
- Annual report, year to Mar 20158 Jul 2015, a zip file
- Annual report, year to Mar 20149 Jul 2014, a zip file
- Annual report, year to Mar 201222 Oct 2013, a zip file
- Annual report, year to Mar 201322 Jul 2013, a zip file
- Annual report, year to Mar 201118 Jul 2011, a zip file
- Annual report, year to Mar 20103 Sep 2010, a zip file
Investor presentations22
- Investor Presentation13 Jan 2026
- Investor Presentation8 Jan 2026
- Press Release- Investor Presentation on Upcoming R&D Day to share strategic updates on Key Programs and R&D Pipeline31 Dec 2025
- Investor Presentation24 Dec 2024
- Investor Presentation19 Dec 2024
17 earlier presentations
- Investor Presentation7 Jan 2024
- Investor Presentation6 Jan 2024
- Investor Presentation2 Nov 2023
- Investor Presentation13 Oct 2022
- Investor Presentation28 Dec 2021
- Investor Presentation16 Dec 2021
- Investor Presentation9 Dec 2021
- Investor Presentation10 Sep 2020
- Investor Presentation19 Sep 2019
- Investor Presentation4 Sep 2018
- Analysts/Institutional Investor Meet/Con. Call Updates - Further to out letter No. SPARC/Sec/SE/2017-18/034 dated 10th August 2017 on the subject, please find enclosed a copy of the presentation by the Company providing update on NCE & NDDS programs, which is self-explanatory.You are requested to kindly take the same on your record & disseminate the information through your website.24 Aug 2017, a zip file
- Presentation by the Company providing update on NCE & NDDS programs.4 Aug 2016, a zip file
- Investor Presentation- Updated on NCE and NDDS Programs.10 Jun 2015, a zip file
- SPARC Management Presentation to update information about New Chemical Entity (NCE) and Novel Drug Delivery Systems (NDDS) research projects of the Company.26 Feb 2014, a zip file
- Company's SPARC presentation which the Company presented in M S Health Conference on September 14, 2011 to update information on New Chemical Entity (NCE) and Novel Drug Delivery Systems (NDDS) research projects of the Company.15 Sep 2011, a zip file
- Company's presentation containing update on NCE and NDDS programs.13 Jun 2011, a zip file
- Investor Presentation held on May 20, 2010 to update information about New Chemical Entity (NCE) and Novel Drug Delivery Systems (NDDS) research projects of the Company.21 May 2010, a zip file
Earnings calls11
- Transcript of the Investor's Call for SPARC R&D Day - Updates on Prioritized Programs13 Jan 2026
- Transcript18 Apr 2024
- Link of Recording17 Apr 2024
- Link of Recording16 Jan 2024
- Transcript15 Jan 2024
6 earlier call documents
- Transcript12 Jan 2024
- Transcript10 Nov 2023
- Link of Recording3 Nov 2023
- Transcript of Investor Presentation28 Oct 2022
- Recording of Audio Playback of the Investor Presentation for Update on Clinical Programs and R&D Pipeline17 Oct 2022
- Transcript of Management Presentation held on May 20, 2010 to update information about New Chemical Entity (NCE) and Novel Drug Delivery Systems (NDDS) research projects of the Company.15 Jun 2010, a zip file
Sun Pharma Advanced Research Company share news and announcements
Newest first. Page 1 of 12.
Oct 2026
4 Oct · Legal
Aug 2026
13 Aug · General Updates
10 Aug · Meeting
10 Aug · Business
10 Aug · Board meeting
10 Aug · Results
Jul 2026
27 Jul · Updates
13 Jul · Management
6 Jul · Updates
Jun 2026
26 Jun · Management
25 Jun · Rescission/termination(s)
May 2026
19 May · General Updates
Apr 2026
Mar 2026
27 Mar · Management
26 Mar · Legal
The exchange asked on 25 Mar 2026
Feb 2026
24 Feb · General Updates
9 Feb · Board meeting
2 Feb · Legal
The exchange asked on 1 Feb 2026
Jan 2026
14 Jan · Board meeting
11 Jan · Board meeting
Dec 2025
3 Dec · Legal
Nov 2025
13 Nov · Updates
10 Nov · Results
Oct 2025
29 Oct · Legal
The exchange asked on 28 Oct 2025
Aug 2025
4 Aug · Results
Jul 2025
28 Jul · Board meeting
8 Jul · Updates
How the price met the news
The first session after each announcement, beside the market.
That dayThe first session's move. The first session's close after the announcement against the close before it, as a per cent change, on prices adjusted for splits and bonuses.Against the Nifty 500Against the Nifty 500. The share's move less the Nifty 500's move the same session, in percentage points (pts).Market median on that newsThe market's median move on that news. The middle first-session move of every listed company that filed the same kind of announcement, half moving more and half less.Five sessionsFive sessions' move. The close five sessions after the announcement against the close before it, as a per cent change.Five sessions against the Nifty 500Five sessions against the Nifty 500. The share's five-session move less the Nifty 500's move over the same five sessions, in percentage points (pts).Volume, times usualVolume, times usual. The session's shares traded divided by the average of the twenty sessions before it.Delivery against usualDelivery against usual. The share of the session's volume delivered into demat accounts, rather than bought and sold again the same day, less its average over the twenty sessions before, in percentage points (pts). Delivery against usual in the glossary
- 10 Aug 2026Resultsdown 2.73%−2.9 pts vs Nifty 500market median −0.7% · five sessions −7.1% (−6.6 pts vs Nifty 500) · volume 1.5× usual · delivery −10.5 pts against usual · The announcement
- 29 Jun 2026Board or managers changedup 2.79%+3.3 pts vs Nifty 500market median 0.0% · five sessions +6.4% (+5.6 pts vs Nifty 500) · volume 0.5× usual · delivery 0.0 pts against usual · The announcement
- 19 May 2026Resultsup 10.81%+10.5 pts vs Nifty 500market median −0.7% · five sessions +43.6% (+41.5 pts vs Nifty 500) · volume 11.7× usual · delivery −31.8 pts against usual · The announcement
- 6 Apr 2026Board or managers changeddown 1.16%−2.4 pts vs Nifty 500market median 0.0% · five sessions +19.6% (+12.8 pts vs Nifty 500) · volume 0.5× usual · delivery −20.7 pts against usual · The announcement
- 30 Mar 2026Board or managers changeddown 4.96%−2.6 pts vs Nifty 500market median 0.0% · five sessions +4.5% (+3.2 pts vs Nifty 500) · volume 1.6× usual · delivery −8.4 pts against usual · The announcement
- 10 Feb 2026Resultsup 1.84%+1.5 pts vs Nifty 500market median −0.7% · five sessions −3.1% (−2.2 pts vs Nifty 500) · volume 0.6× usual · delivery −1.2 pts against usual · The announcement
- 11 Nov 2025Resultsdown 0.21%−0.6 pts vs Nifty 500market median −0.7% · five sessions 0.0% (−1.5 pts vs Nifty 500) · volume 0.4× usual · delivery −10.2 pts against usual · The announcement
- 4 Aug 2025Resultsdown 0.82%−1.6 pts vs Nifty 500market median −0.7% · five sessions −4.8% (−3.8 pts vs Nifty 500) · volume 0.6× usual · delivery −4.5 pts against usual · The announcement
- 6 Mar 2025Credit ratingup 1.16%+0.2 pts vs Nifty 500market median 0.0% · five sessions −0.1% (−0.1 pts vs Nifty 500) · volume 0.9× usual · delivery −8.7 pts against usual · The announcement
- 11 Feb 2025Resultsdown 4.05%−2.1 pts vs Nifty 500market median −0.7% · five sessions −12.3% (−8.9 pts vs Nifty 500) · volume 1.3× usual · delivery +2.5 pts against usual · The announcement
14 earlier announcements
- 20 Jan 2025Board or managers changedup 0.75%+0.2 pts vs Nifty 500market median 0.0% · five sessions −4.3% (−2.7 pts vs Nifty 500) · volume 0.8× usual · delivery +10.1 pts against usual · The announcement
- 4 Nov 2024Resultsdown 5.01%−3.7 pts vs Nifty 500market median −0.7% · five sessions −3.9% (−3.2 pts vs Nifty 500) · volume 2.4× usual · delivery −8.6 pts against usual · The announcement
- 5 Aug 2024Resultsdown 4.08%−1.0 pts vs Nifty 500market median −0.7% · five sessions −3.3% (−1.9 pts vs Nifty 500) · volume 1.3× usual · delivery −0.3 pts against usual · The announcement
- 6 Jun 2024Board or managers changedup 4.69%+3.2 pts vs Nifty 500market median 0.0% · five sessions +5.9% (+1.6 pts vs Nifty 500) · volume 1.3× usual · delivery −3.2 pts against usual · The announcement
- 27 May 2024Resultsdown 2.57%−2.6 pts vs Nifty 500market median −0.7% · five sessions −8.0% (−6.2 pts vs Nifty 500) · volume 0.6× usual · delivery −5.0 pts against usual · The announcement
- 27 May 2024Board or managers changeddown 2.57%−2.6 pts vs Nifty 500market median 0.0% · five sessions −8.0% (−6.2 pts vs Nifty 500) · volume 0.6× usual · delivery −5.0 pts against usual · The announcement
- 3 Nov 2023Board or managers changedup 1.01%+0.4 pts vs Nifty 500market median 0.0% · five sessions +7.9% (+6.0 pts vs Nifty 500) · volume 0.6× usual · delivery +0.1 pts against usual · The announcement
- 7 Aug 2023Resultsdown 3.04%−3.4 pts vs Nifty 500market median −0.7% · five sessions −5.3% (−5.1 pts vs Nifty 500) · volume 0.6× usual · delivery +7.8 pts against usual · The announcement
- 22 May 2023Resultsdown 4.76%−5.4 pts vs Nifty 500market median −0.7% · five sessions −6.1% (−8.0 pts vs Nifty 500) · volume 7.8× usual · delivery −8.9 pts against usual · The announcement
- 7 Nov 2022Resultsdown 2.34%−2.9 pts vs Nifty 500market median −0.7% · five sessions −6.1% (−6.9 pts vs Nifty 500) · volume 0.6× usual · delivery +7.0 pts against usual · The announcement
- 8 Aug 2022Resultsdown 0.98%−1.6 pts vs Nifty 500market median −0.7% · five sessions −2.5% (−5.0 pts vs Nifty 500) · volume 1.8× usual · delivery −9.8 pts against usual · The announcement
- 17 May 2022Resultsup 2.48%−0.1 pts vs Nifty 500market median −0.7% · five sessions −4.3% (−6.2 pts vs Nifty 500) · volume 2.0× usual · delivery −17.0 pts against usual · The announcement
- 7 Feb 2022Resultsdown 2.73%−1.3 pts vs Nifty 500market median −0.7% · five sessions −4.7% (−3.4 pts vs Nifty 500) · volume 0.4× usual · delivery −4.4 pts against usual · The announcement
- 2 Mar 2020Board or managers changeddown 3.36%−2.7 pts vs Nifty 500market median 0.0% · five sessions +1.5% (+3.4 pts vs Nifty 500) · volume 0.6× usual · delivery −6.4 pts against usual · The announcement
Sun Pharma Advanced Research Company results filing dates and deadlines
Listed companies must file quarterly results within 45 days, and the year's within 60.
Days to fileDays to file. The days from the period's end to the day the results reached the exchange.DeadlineDeadline, days. The days the rules allow from the period's end: 45 for a quarter or half year, and 60 for the year and the March quarter filed with it. A company that listed after the period ended has until 21 days after its listing where that is later.